Mechanisms of Disease Progression in NASH: New Paradigms

Clinics in Liver Disease

Volumn 16, Issue 3, 2012, Pages 549-565

  Bohinc, Brittany N ^a   Diehl, Anna Mae ^b  

^a DUKE UNIVERSITY HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Hedgehog signaling pathway; Hepatic fibrosis; Hepatocellular carcinoma; NASH; Nonalcoholic steatohepatitis

Indexed keywords

OSTEOPONTIN; SONIC HEDGEHOG PROTEIN;

APOPTOSIS; AUTOCRINE EFFECT; CANCER RISK; CANONICAL ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MODEL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROGENESIS; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER REGENERATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PARACRINE SIGNALING; REVIEW; SIGNAL TRANSDUCTION; STELLATE CELL;

ANIMALS; APOPTOSIS; AUTOCRINE COMMUNICATION; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; FATTY LIVER; HEDGEHOG PROTEINS; HEPATIC STELLATE CELLS; HUMANS; INFLAMMATION; LIVER; LIVER CIRRHOSIS; MICE; PARACRINE COMMUNICATION; RATS; RISK FACTORS;

EID: 84864112587     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.05.002     Document Type: Review

References (138)

1. Boppidi H., Daram S.R. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome. Postgrad Med 2008, 120:E01-E07.
2. Clark J.M. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006, 40(Suppl 1):S5-S10.
3. The National Digestive Diseases Information Clearinghouse Web site, National Institute of Diabetes and Digestive and Kidney Diseases 2006, NIH Publication No. 07-4921, National Institutes of Health, Available at:, Accessed January 8, 2012. http://digestive.niddk.nih.gov/ddiseases/pubs/nash/.
4. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-S112.
5. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
6. Rahbari N.N., Mehrabi A., Mollberg N.M., et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011, 253:453-469.
7. Luedde T., Schwabe R.F. NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011, 8:108-118.
8. McCullough A.J. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002, 34(3):255-265.
9. Day C. Pathogenesis of steatohepatitis. Best practice and research. Clin Gastroenterol 2002, 16(7):663.
10. Abdelmalek M.F., Suzuki A., Guy C., et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51(6):1961-1971.
11. de Almeida I.T., Cortez-Pinto H., Fidalgo G., et al. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr 2002, 21(3):219-223.
12. Cassader M., Gambino R., Musso G., et al. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids 2001, 36(10):1117-1124.
13. Marchesini G., Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 2002, 35(2):497-499.
14. Bernard S., Touzet S., Personne I., et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000, 43(8):995-999.
15. Charlton M., Sreekumar R., Rasmussen D., et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002, 35(4):898-904.
16. Tessari P., Coracina A., Cosma A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2009, 19(4):291-302.
17. Yang S., Zhu H., Li Y., et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000, 378:259-268.
18. Mantena S.K., Vaughn D.P., Andringa K.K., et al. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J 2009, 417:183-193.
19. Collison K.S., Saleh S.M., Bakheet R.H., et al. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity (Silver Spring) 2009, 17(11):2003-2013.
20. Allard J.P. Other disease associations with non-alcoholic fatty liver disease (NAFLD). Best Pract Res Clin Gastroenterol 2001, 16(5):783-795.
21. D'Albuquerque L.A., Gonzalez A.M., Wahle R.C., et al. Liver transplantation for subacute hepatocellular failure due to massive steatohepatitis after bariatric surgery. Liver Transpl 2009, 14(6):881-885.
22. Maruhama Y., Ohneda A., Tadaki H., et al. Hepatic steatosis and the elevated plasma insulin level in patients with endogenous hypertriglyceridemia. Metabolism 1975, 24(5):653-664.
23. Sen D., Dagdelen S., Erbas T. Hepatosteatosis with hypobetalipoproteinemia. J Natl Med Assoc 2007, 99(3):284-286.
24. Cave M., Deacluc I., Mendez C., et al. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 2007, 18(3):184-195.
25. Hooper J.E., Scott M.P. Communicating with hedgehogs. Nat Rev Mol Cell Biol 2005, 6:306-317.
26. Schuske K., Hooper J.E., Scoot M.P. Patched overexpression causes loss of wingless expression in Drosophila embryos. Dec Biol 1994, 164:300-311.
27. Varjosalo M., Li S.P., Taipale J. Divergence of hedgehog signal transduction mechanism between drosophila and mammals. Dev Cell 2006, 10:177-186.
28. Sicklick J.K., Li Y.X., Choi S.S., et al. Role for hedgehog signaling in hepatic stellate cell activation and viability. Lab Invest 2005, 85(11):1368-1380.
29. Ramalho-Santos M., Melton D.A., McMahon A.P. Hedgehog signals regulate multiple aspects of gastrointestinal development. Dev 2000, 127(12):2763-2772.
30. Hebrok M., Kim S.K., St Jacques B., et al. Regulation of pancreas development by hedgehog signaling. Dev 2000, 127(22):4905-4913.
31. Van den Brink G.R. Hedgehog signaling in development and homeostasis of the gastrointestinal tract. Physiol Rev 2007, 87:1343-1375.
32. Pan Y., Wang C., Wang B. Phosphorylation of Gli2 by protein kinase A is required for Gli2 processing and degradation and the Sonic Hedgehog-regulated mouse development. Dev Biol 2009, 326(1):177-189.
33. Lauth M., Toftgard R. Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. Cell Cycle 2007, 6:2458-2463.
34. Riobo N.A., Lu K., Ai X., et al. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci U S A 2006, 103:4505-4510.
35. Dennler S., Andre J., Alexaki I., et al. Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res 2007, 67(14):6981-6986.
36. Lauth M., Toftgård R. Non-canonical activation of Gli1 transcription factors: implications for targeted anti-cancer therapy. Cell Cycle 2007, 6:2458-2463.
37. Tada M., Kanai F., Tanaka Y., et al. Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma. Clin Cancer Res 2008, 14:3768-3776.
38. Wolf I., Bose S., Desmond J.C., et al. Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer. Breast Cancer Res Treat 2007, 105:139-155.
39. Yakushiji N., Suzuki M., Satoh A., et al. Correlation between Shh expression and DNA methylation status of the limb-specific Shh enhancer region during limb regeneration in amphibians. Dev Biol 2007, 312:171-182.
40. Zavros Y., Waghray M., Tessier A., et al. Reduced pepsin A processing of Sonic Hedgehog in parietal cells precedes gastric atrophy and transformation. J Biol Chem 2007, 292:33265-33274.
41. Porter J.A., von Kessler D.P., Ekker S.C., et al. The product of hedgehog autoproteolytic cleavage active in local and long-range signaling. Nature 1995, 374:363-366.
42. Porter J.A., Young K.E., Beachy P.A. Cholesterol modification of hedgehog signaling proteins in animal development. Science 1996, 274:255-259.
43. Witek R.P., Yang L., Liu R., et al. Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. Gastroenterology 2009, 136:320-330.
44. Burke R., Nellen D., Bellotto M., et al. Dispatched, a novel sterol-sensing domain protein dedicated to the release of cholesterol-modified hedgehog from signaling cells. Cell 1999, 99:803-815.
45. Sicklick J.K., Li Y.X., Jayaraman A., et al. Hedgehog signaling maintains resident hepatic progenitors throughout life. Am J Physiol Gastrointest Liver Physiol 2006, 290:G859-G870.
46. Choi S.S., Omenetti A., Witek R.P., et al. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009, 297:G1093-G1106.
47. Rangwala F., Guy C.D., Lu J., et al. Increased production of Sonic Hedgehog by ballooned hepatocytes. J Pathol 2011, 224:401-410.
48. Omenetti A., Yang L., Li Y.X., et al. Hedgehog-mediated mesenchymal-epithelial interactions modulate hepatic response to bile duct ligation. Lab Invest 2007, 87:499-514.
49. Fleig S.V., Choi S.S., Yang L., et al. Hepatic accumulation of hedgehog-reactive progenitors increases with severity of fatty liver damage in mice. Lab Invest 2007, 87:1227-1239.
50. Syn W.K., Witek R.P., Curbishley S.M., et al. Role for hedgehog pathway in regulating growth and function of invariant NKT cells. Eur J Immunol 2009, 39:1879-1892.
51. Jung Y., McCall S.J., Li Y.X., et al. Bile ductules and stromal cells express hedgehog ligands and/or hedgehog target genes in primary biliary cirrhosis. Hepatology 2007, 45:1091-1096.
52. Jung Y., Brown K.D., Witek R.P., et al. Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans. Gastroenterol 2008, 134(5):1532-1543.
53. Sanchez A., Fabregat I. Growth factor- and cytokine-driven pathways governing liver stemness and differentiation. World J Gastroenterol 2010, 16(41):5148-5161.
54. Omenetti A., Choi S., Michelotti G., et al. Hedgehog signaling in the liver. Journal of Hepatology 2011, 54:366-373.
55. Kurosaka K., Takahashi M., Watanabe N., et al. Silent cleanup of very early apoptotic cells by macrophages. J Immunol 2003, 171:4672-4679.
56. Majno G., Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995, 146:3-15.
57. Faubion W.A., Gores G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004, 39:273-278.
58. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35:495-516.
59. Canbay A., Friedman S., Gores G.J., et al. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004, 39:273-278.
60. Canbay A., Higuchi H., Bronk S.F., et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002, 123:1323-1330.
61. Faouzi S., Burckhardt B.E., Hanson J.C., et al. Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway. J Biol Chem 2001, 276:49077-49082.
62. Rogers H.W., Callery M.P., Deck B., et al. Listeria monoctogenes induces apoptosis of infected hepatocytes. J Immunol 1996, 156:679-684.
63. Ebe Y., Hasegawa G., Takatsuka H., et al. The role of Kupffer cells and regulation of neutrophil migration into the liver by macrophage inflammatory protein-2 in primary listeriosis in mice. Pathol Int 1999, 49:519-532.
64. Lawson J.A., Fisher M.A., Simmons C.A., et al. Parenchymal cell apoptosis as a signal for sinusoidal sequestration and transendothelial migration of neutrophils in murine models of endotoxin and Fas-antibody-induced liver injury. Hepatology 1998, 28:761-767.
65. Omenetti A., Syn W.K., Jung Y., et al. Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. Hepatology 2009, 50:518-527.
66. Kiener P.A., Davis P.M., Rankin B.M., et al. Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol 1997, 159:1594-1598.
67. Geske F.J., Monks J., Lehman L., et al. The role of the macrophage in apoptosis: hunter, gatherer, and regulator. Int J Hematol 2002, 76:16-26.
68. Feldstein A.E., Canbay A., Angulo P., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-443.
69. Wiechowska A., Zein N.N., Yerian L.M., et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44:27-33.
70. Puri P., Mirshahi F., Cheung O., et al. Activation and dysregulation of the unfolded protein response in non-alcoholic fatty liver disease. Gastroenterology 2008, 134:568-576.
71. Ghosh S., May M.J., Kopp E.B. NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16:225-260.
72. Ribeiro P.S., Cortez-Pinto H., Sola S., et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004, 99:1708-1717.
73. De Lalla C., Galli G., Aldrighetti L., et al. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol 2004, 173:1417-1425.
74. Geissmann F., Cameron T.O., Sidobre S., et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 2005, 3:e113.
75. Kronenberg M. Toward an understanding of NKT: progress and paradoxes. Annu Rev Immunol 2005, 23:877-900.
76. Mallevaey T., Fontaine J., Breuil L., et al. Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis. Infect Immun 2007, 75:2171-2180.
77. Syn W.K., Oo Y.H., Pereira T.A., et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 2010, 51:1998-2007.
78. Tajiri K., Shimizu Y., Tsuneyama K., et al. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009, 21:673-680.
79. Onchoa B., Syn W.K., Delgado I., et al. Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. Hepatology 2010, 51:1712-1723.
80. Zhang L., Theise N., Chua M., et al. The stem cell niche of human livers: symmetry between development and regeneration. Hepatology 2008, 48:1598-1607.
81. Jung Y., Witek R.P., Syn W.K., et al. Signals from dying hepatocytes trigger growth of liver progenitors. Gut 2010, 59:655-665.
82. Pereira T.A., Witek R.P., Syn W.K., et al. Viral factors induce hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Invest 2010, 90(12):1690-1703.
83. Syn W.K., Jung Y., Omenetti A., et al. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009, 137:1478-1488. e1478.
84. Omenetti A., Popov Y., Jung Y., et al. The hedgehog pathway regulates remodeling responses to biliary obstruction in rats. Gut 2008, 57:1275-1282.
85. Harmon E.B., Ko A.H., Kim S.K. Hedgehog signaling in gastrointestinal development and disease. Curr Mol Med 2002, 2:67-82.
86. Oue T., Yoneda A., Uehara S., et al. Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J Pediatr Surg 2010, 45:387-392.
87. Acloque H., Adams M.S., Fishwick K., et al. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009, 119:1438-1449.
88. Choi S.S., Witek R.P., Yang L., et al. Activation of Rac1 promotes hedgehog-mediated acquisition of the myofibroblastic phenotype in rat and human hepatic stellate cells. Hepatology 2010, 52:278-290.
89. Baum B., Settleman J., Quinlan M.P. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 2008, 19:294-308.
90. Omenetti A., Porrello A., Jung Y., et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008, 118:3331-3342.
91. Omenetti A., Bass L.M., Anders R.A., et al. Hedgehog activity, epithelial-mesenchymal transitions, and biliary dysmorphogenesis in biliary atresia. Hepatology 2011, 53(4):1246-1258.
92. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
93. Shao D.O., Suresh R., Vakil V., et al. Pivotal advance: th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 2008, 83:1323-1333.
94. Choi S.S., Syn W.K., Karaca G.F., et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J of Biol Chem 2010, 285(47):36551-36560.
95. Choi S.S., Omenetti A., Syn W.K., et al. The role of hedgehog signaling in fibrogenic liver repair. Int J Biochem Cell Biol 2011, 43:238-244.
96. Witek R.P., Stone W.C., Karaca G., et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009, 50:1421-1430.
97. Miyazaki K., Okada Y., Yamanaka O., et al. Corneal wound healing in an osteopontin-deficient mouse. Invest Ophthalmol Vis Sci 2008, 49:1367-1376.
98. Fujita N., Fujita S., Okada Y., et al. Impaired angiogenic response in the corneas of mice lacking osteopontin. Invest Ophthalmol Vis Sci 2010, 51:790-794.
99. Lorena D., Darby I.A., Gadeau A.P., et al. Osteopontin expression in normal and fibrotic liver. Altered liver healing in osteopontin-deficient mice. J Hepatol 2006, 44:383-390.
100. Gómez-Ambrosi J., Catalán V., Ramírez B., et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 2007, 92(9):3719-3727.
101. Bertola A., Deveaux V., Bonnafous S., et al. Elevated expression of osteopontin may be related to tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 2009, 58(1):125-133.
102. Lee S.H., Seo G.S., Park Y.N., et al. Effects and regulation of osteopontin in rate hepatic stellate cells. Biochem Pharmacol 2004, 68(12):2367-2378.
103. Zhao L., Li T., Wang Y., et al. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract 2008, 62(7):1056-1062.
104. Syn W.K., Choi S.S., Liaskou E., et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis in nonalcoholic steatohepatitis. Hepatology 2011, 53(1):106-115.
105. Harada K., Ozaki S., Sudo Y., et al. Osteopontin is involved in the formation of epithelioid granuloma and bile duct injury in primary biliary cirrhosis. Pathol Int 2003, 53(1):8-17.
106. Hoehme S., Brulport M., Bauer A., et al. Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration. Proc Natl Acad Sci U S A 2010, 107:10371-10376.
107. Rojkind M., Philips G., Diehl A.M. Microarchitecture of the liver: a jigsaw puzzle. J of Hepatology 2011, 54:187-188.
108. Rudolph K.L., Trautwein C., Kubicks S., et al. Differential regulation of extracellular matrix synthesis during liver regeneration after partial hepatectomy in rates. Hepatology 1999, 30:1159-1166.
109. Asai J., Takenaka H., Kusano K.F., et al. Topical Sonic Hedgehog gene therapy accelerates wound healing in diabetes by enhancing endothelial progenitor cell-mediated microvascular remodeling. Circulation 2006, 113:2413-2424.
110. Vokes S.A., Yatskievch T.A., Heimark R.L., et al. Hedgehog signaling is essential for endothelial tube formation during vasculogenesis. Development 2004, 131:4371-4380.
111. Yang L., Wang Y., Mao H., et al. Sonic Hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J Hepatol 2008, 48:98-106.
112. Semela D., Das A., Langer D., et al. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology 2008, 135:671-679.
113. Taura K., De Minicis S., Seki E., et al. Hepatic stellate cells secrete angiopoietin 1 that induces aniogenesis in liver fibrosis. Gastroenterology 2008, 135:1729-1738.
114. Ankoma-Sey V., Wang Y., Dai Z., et al. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 2000, 31:141-148.
115. Guy C.D., Suzuki A., Zdanowicz M., et al. Hedgehog pathway activation parallels histologic severity in nonalcoholic fatty liver disease. Hepatology 2011, 10.1002/hep.25559.
116. Gramlich T., Kleiner D.E., McCullough A.J., et al. Pathologic features associated with fibrosis in non-alcoholic fatty liver disease. Hum Pathol 2004, 35:196-199.
117. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
118. Brunt E.M. Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis 2009, 13:533-544.
119. Oniscu A., James R.M., Morris R.G., et al. Expression of Sonic Hedgehog pathway genes is altered in colonic neoplasia. J Pathol 2004, 203(4):909-917.
120. Berman D.M., Karhadkar S.S., Maitra A., et al. Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003, 425:846-851.
121. Thayer S.P., Di Magliano M.P., Heiser P.W., et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
122. Sicklick J.K., Li Y.X., Jayaraman A., et al. Dysregulation of the hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006, 27:748-757.
123. Toftgard R. Hedgehog signaling in cancer. Cell Mol Life Sci 2000, 57:1720-1731.
124. Saldanha G. The hedgehog signaling pathway in cancer. J Pathol 2001, 193:427-432.
125. Freeman J.W., Wang Y., Glies F.J. Epigenetic modulation and attacking the hedgehog pathway: potentially synergistic therapeutic targets for pancreatic cancer. Cancer Biol Ther 2009, 8:1227-1239.
126. Beachy P.A., Karhadkar S.S., Berman D.M. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004, 432:324-331.
127. Villanueva A., Newell P., Chiang D.Y., et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27:55-76.
128. Harnois D.M., Que F.G., Celli A., et al. Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology 1997, 26:884-890.
129. Kurita S., Mott J.L., Almada L.L., et al. GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis. Oncogene 2010, 29:4848-4858.
130. Takeda K., Kojima Y., Ikejima K., et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci U S A 2008, 105:10895-10900.
131. Mott J.L., Kobayashi S., Bronk S.F., et al. Mir-29 regulated Mcl-1 protein expression and apoptosis. Oncogene 2007, 26:6133-6140.
132. Eichenmuller M., Gruner I., Hagl B., et al. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 2009, 49:482-490.
133. Yang M.H., Chen C.L., Chau G.Y., et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 2009, 50(5):1464-1474.
134. Matsuo N., Shiraha H., Fujikawa T., et al. Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer 2009, 9:240.
135. Chen L., Chan T.H., Yuan Y.F., et al. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest 2010, 120(4):1178-1191.
136. Philips G.M., Chan I.S., Swiderska M., et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS ONE 2011, 6(9). e23943.
137. Xu Y., Chenna V., Hu C., et al. A polymeric nanoparticle encapsulated hedgehog pathway inhibitor HPI-1 inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2012, 18(5):1291-1302.
138. Kim Y., Yoon J.W., Xiao X., et al. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res 2007, 67(8):3583-3593.